- Heartburn Slideshow: Foods to Eat, Foods to Avoid
- 10 Facts About the Amazing Brain
- Weight Gain Shockers Slideshow Pictures
What is Revcovi, and how does it work?
Revcovi (elapegademase-lvlr) is a recombinant adenosine deaminase indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.
What is the dosage for Revcovi?
Patients Transitioning From Adagen To Revcovi
- If a patient's weekly Adagen dose is unknown, or a patient's weekly Adagen dose is at or lower than 30 U/kg, the recommended minimum starting dose of Revcovi is 0.2 mg/kg, intramuscularly, once a week.
- If a patient's weekly Adagen dose is above 30 U/kg, an equivalent weekly Revcovi dose (mg/kg) should be calculated using the following conversion formula:
- Revcovi dose in mg/kg = Adagen dose in U/kg/150
- Subsequent doses may be increased by increments of 0.033 mg/kg weekly if trough ADA activity is under 30 mmol/hr/L, trough deoxyadenosine nucleotides (dAXP) are above 0.02 mmol/L, and/or the immune reconstitution is inadequate based on the clinical assessment of the patient.
- The total weekly dose may be divided into multiple intramuscular (IM) administrations during a week.
- The starting weekly dose of Revcovi is 0.4 mg/kg based on ideal body weight or actual weight whichever is greater, divided into two doses (0.2 mg/kg twice a week), intramuscularly, for a minimum of 12 to 24 weeks until immune reconstitution is achieved.
- After that, the dose may be gradually adjusted down to maintain trough ADA activity over 30 mmol/hr/L, trough dAXP level under 0.02 mmol/L, and/or to maintain adequate immune reconstitution based on clinical assessment of the patient.
- The optimal long-term dose and schedule of administration should be established by the treating physician for each patient individually and may be adjusted based on the laboratory values for trough ADA activity, trough dAXP level, and/or on the treating physician's medical assessment of the patient's clinical status.
Is Revcovi safe to use while pregnant or breastfeeding?
- Adequate and well-controlled studies with Revcovi have not been conducted in pregnant women to inform a drug-associated risk.
- It is not known whether Revcovi can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
- Human or animal lactation studies have not been conducted to assess the presence of Revcovi in breast milk, the effects on the breastfed infant, or the effects on milk production for the mother.
Revcovi (elapegademase-lvlr) is a recombinant adenosine deaminase indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID), an inherited disorder that harms the immune system, in pediatric and adult patients. Common side effects of Revcovi include cough and vomiting. Drug interactions with Revcovi are not known.
Multimedia: Slideshows, Images & Quizzes
16 Foods That Boost and Improve Your Immune System
Help fight colds, flu, as well as viruses like coronavirus with foods that boost and improve your immune system. Reach for...
Top 15 Immune System Boosters
Immune system boosters include foods, supplements, and lifestyle habits to help you fight off infections. A healthy immune system...
How Your Immune System Functions
What is the immune system and its function? Your immune system finds and kills germ invaders when you are sick from a cold, the...
Cold, Flu, and Cough: Things That Suppress Your Immune System
A strong immune system is your best protection against infections and illnesses. Find out what can weaken that defense.
Treatment & Diagnosis
Latest Medications News
Daily Health News
Health Solutions From Our Sponsors
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.